Novo Nordisk CEO Provides Timeline for CagriSema Obesity Drug Launch
Novo Nordisk CEO Mike Doustdar announced that the company is already in production mode for its next-generation obesity treatment, CagriSema. The drug, which combines semaglutide with cagrilintide, aims to provide superior weight loss results compared to existing treatments. While a specific launch date was not finalized, the company is targeting FDA approval and an initial rollout as early as late 2025 or early 2026. CagriSema has shown significant efficacy in clinical trials, including the REDEFINE studies where weight loss reached up to 22.7% in adults without type 2 diabetes. The company plans a multi-channel distribution strategy, utilizing e-health platforms and its own NovoCare pharmacy to facilitate direct-to-consumer access. Although pricing strategies remain undisclosed, Novo Nordisk emphasized that affordability will be a key consideration for the U.S. market.